Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828

Drugs under Experimental and Clinical Research

Volumn 29, Issue 2, 2003, Pages 53-67

  Wojciechowski, J ^a   Lovborg H ^b   Wȩsierska Ga̧dek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; GUANIDINE DERIVATIVE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROBENECID; PROTEIN P53; SERINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; UPREGULATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; CYANIDES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GUANIDINES; HUMANS; IMMUNOBLOTTING; MICE; PHOSPHORYLATION; POLY ADENOSINE DIPHOSPHATE RIBOSE; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0042027970     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sherr C.J. Cancer cell cycles. Science, 274, 1672, 1996.
2. 1-phase progression. Genes Dev., 13, 1501, 1999.
3. Mowat M.R. p53 in tumor progression: Life, death and everything. Adv. Canc. Res., 74, 25, 1998.
4. Prives C., Hall P.A. The p53 pathway. J. Pathol., 187, 112, 1999.
5. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science, 253, 49, 1991.
6. Hainault P., Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res., 77, 81, 2000.
7. Appella E., Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem., 268, 2764, 2001.
8. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237, 1992.
9. El-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genetics, 1, 45, 1992.
10. 1 cyclin dependent kinases. Cell, 75, 805, 1993.
11. El-Deiry W.S., Tokino T, Velculescu V.E. WAF-1, a potential mediator of p53 tumour suppression. Cell, 75, 817, 1993.
12. Flores-Rozas H., Kelman Z., Dean F.B., et al. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase-δ holoen-zyme. Proc. Natl. Acad. Sci. USA, 91, 8655, 1994.
13. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574, 1994.
14. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371, 534, 1994.
15. Chuang L.S., Ian H.H., Koh T.W., Ng H.H., Xu G., Li B.F. Human DNA-(cytosine -5)methyltransferase-PCNA complex a target for p21WAF1. Science, 277, 1996, 1997.
16. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-κB in p53-mediated programmed cell death. Nature, 404, 892, 2000.
17. Shou C., Ottosen E., Björkling F., et al. Novel cyanoguanidines with potent oral antitumour activity. Bioorg. Med. Chem. Lett., 7, 3095, 1997.
18. Wang Z.-Q., Auer B., Stingl L., Berghammer H., Haidacher D., Schweiger M., Wagner E.F. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev., 9, 509, 1995.
19. Wang Z.-Q., Stingl L., Jantsch M., Los M., Schulze-Osthoff K., Wagner E.F. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev., 11, 2347, 1997.
20. Herceg Z., Wang Z.-Q. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol. Cell. Biol., 19, 5124, 1999.
21. Lövborg H., Wojciechowski J., Larsson R., Wesierska-Gadek J. Action of a novel anticancer agents, CHS 828, on mouse fibroblasts: Increased sensitivity of cells lacking poly(ADP-ribose)polymerase-1. Cancer Res., 62, 4206, 2002.
22. Wesierska-Gadek J., Schloffer D., Kotala V., Horky M. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy. Int. J. Cancer, 101, 128, 2002.
23. Barnas C., Martel-Planche G., Furukawa Y., Hollstein M., Montesano R., Hainault P. Inactivation of p53 protein in cell line derived from human esophageal cancers. Int. J. Cancer, 71, 79, 1997.
24. Kovar H., Jug G., Printz D., Bartl S., Schmid G., Wesierska-Gadek J. Characterization of distinct consecutive phases in nongenotoxic p53-induced apoptosis in Ewing tumor cells and rate limiting role caspase 8. Oncogene, 19, 4096, 2000.
25. Wurzer G., Herceg Z., Wesierska-Gadek J. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase-1 attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res., 60, 4238, 2000.
26. Jonsson E., Friberg L.E., Karlsson M.O., et al. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats. Cancer Chemother. Pharmacol., 46, 493, 2000.
27. Hjarnaa P.J., Jonsson E., Latini S., et al. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res., 59, 5751, 1999.
28. Wesierska-Gadek J., Wang Z.-Q., Schmid G. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res., 59, 28, 1999.
29. Wesierska-Gadek J., Bohrn E., Herceg Z., Wang Z-Q., Wurzer G. Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteosome inhibitors. J. Cell. Biochem. 78, 681, 2000.
30. D'Amours D., Desnoyers S., D'Silvia I., Poirier G.G. Poly(ADP-ribosyl)ation reactions in the regulations of nuclear functions. Biochem. J., 342, 249, 1999.
31. Yu S.-W., Wang H., Poltras M.F., et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science, 297, 259, 2002.
32. Wesierska-Gadek J., Schmid G. Overexpressed poly(ADP-ribose) polymerase delays the release of fat cells from p53-mediated G1 checkpoint. J. Cell. Biochem., 80, 85, 2000.
33. Wesierska-Gadek J., Wojciechowski J., Larsson R., Lövborg H. Activation of wt p53 protein in normal and tumor cells by a novel anti-cancer drug CHS 828. Eur. J. Cancer, 38 (Suppl. 7), S109, 2002.
34. Martinsson P., de la Torre M., Binderup L., Nygren P., Larsson R. Cell death with atypical features induced by the novel anti-tumoral drug CHS 828, in human U-937 GTB cells. Eur. J. Pharmacol., 417, 181, 2001.
35. Lövborg H., Martinsson P., Gullbo J., Ekelund S., Nygren P., Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem. Pharmacol., 63, 1491, 2002.
36. Olsen L.S., Larsson R., Binderup L., Madsen M.W. CHS 828 inhibits activity of the IκBβ kinase in vitro and the transcriptional activity of NF-κB in the human monocytic leukemia THP-1 cells. Eur. J. Cancer, 38 (Suppl. 7), S63, 2002.